Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study)

Galderisi, Maurizio; Anderson, Keaven M.; Wilson, Peter W.F.; Levy, Daniel

doi:10.1016/0002-9149(91)90716-x

Cited by 504 publications

(282 citation statements)

References 28 publications

Supporting

Mentioning

244

Contrasting

Unclassified

Order By: Relevance

“…No attempt was made to assess the effects of treatment on different categories of CV events in view of the total number of events in patients with LVH being only 82. The baseline incidence of LVH (12%) in this population is less than that reported previously for diabetic patients [25,26] and patients with chronic kidney disease [11,27,28]. Possible reasons for this include the inclusion/exclusion criteria, which resulted in a low prevalence of CV disease [14] and the reasonably well-controlled BP in many subjects at baseline.…”

Section: Discussionmentioning

confidence: 73%

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Boner

Cooper²,

McCarroll

et al. 2005

Diabetologia

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 73%

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Boner

Cooper²,

McCarroll

et al. 2005

Diabetologia

View full text Add to dashboard Cite

show abstract

“…41 To account for the influence of body composition on LVM, various estimates of body size have been used to normalise LVM, including dividing mass by BSA 42 or by height 2.7 (ref. 22).…”

Section: Discussionmentioning

confidence: 99%

Geographic variation in left ventricular mass and mass index: a systematic review

et al. 2011

View full text Add to dashboard Cite

Left ventricular (LV) hypertrophy, defined as an abnormal increase in LV mass (LVM), is an important prognostic indicator and therapeutic target. LVM is often divided by body surface area to derive indexed mass; however, this does not correctly identify pathological LV hypertrophy in all people, especially when body composition is altered, or in different ethnic groups. We evaluated published ranges of echocardiographic LVM in healthy adult populations from different countries, excluding control groups, and compared them with the American Society of Echocardiography reference ranges. A total of 33 studies met the inclusion criteria. In men and women, there was wide variation in the ranges of LVM with a tendency for the upper limit to increase geographically westward; this variation remained for indexed mass. Several ranges fell outside the upper reference limits: in men, 13 of the mass ranges and 16 of indexed mass; and in women, 8 mass and 16 indexed mass. This review has shown that current guidelines may need revision as some published series suggest that greater LV mass should be considered normal. This may be explained by ethnic differences and supports the need for widely applicable and ethnically diverse reference ranges to be established.

show abstract

“…The first step towards achieving this is to assess the prevalence of unsuspected LVH in routine diabetic patients, and this has not been addressed by any other large study. Early studies showed that diabetes is indeed associated with increased left ventricular mass [28], but there is no previous large study of its prevalence in a group of routine diabetic clinic patients. We therefore assessed the epidemiology of left ventricular abnormalities in type 2 diabetic patients to see whether therapeutic opportunities to reduce the high death rates in diabetics could be identified by routine echocardiography of all diabetic patients.…”

Section: Discussionmentioning

confidence: 99%

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

2005

View full text Add to dashboard Cite

Aims/hypothesis: Patients with type 2 diabetes mellitus are at greater cardiovascular risk than the general population. Although it is widely acknowledged that diabetes is a risk factor for coronary artery disease, the increased prevalence of potentially lethal left ventricular abnormalities in this population is less well appreciated. Methods: We carried out an echocardiographic study of 500 subjects with type 2 diabetes mellitus to assess the prevalence of left ventricular hypertrophy (LVH) and left ventricular systolic dysfunction (LVSD). We also assessed whether abnormalities in diastolic filling parameters were present. Results: Of the 371 patients in whom left ventricular mass could be successfully assessed, 264 had LVH (71%). Left ventricular systolic dysfunction was much less common, being present in 16/385 patients (4.2%). Long axis contraction was abnormal in 29/429 patients (6.8%). Diastolic filling abnormalities were present in 178/435 (41%) of patients who could be classified using the selected criteria. Conclusions: We conclude that left ventricular abnormalities are common in type 2 diabetic patients. As medical therapy is available for both LVH and LVSD and has been demonstrated to reduce cardiovascular death, these left ventricular abnormalities could be ideal targets for screening, followed by selective therapeutic intervention.

show abstract

Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (The Framingham Heart Study)

Cited by 504 publications

References 28 publications

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

Geographic variation in left ventricular mass and mass index: a systematic review

The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus

Contact Info

Product

Resources

About